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A human leukocyte antigen A24-restricted CD8+ cytotoxic T-cell clone specific for gp4l of human
immunodeficiency virus type 1 was isolated from an infected individual. The epitope was localized to amino
acids 584 to 591 (YLKDQQLL, NL43 env sequence) of gp4l by using a panel of recombinant vaccinia viruses
that contain truncated env genes and synthetic peptides. The clone killed autologous B-lymphoblastoid cell lines
pulsed with a synthetic peptide reflecting the sequence of the IIIB and MN strains. This clone, however, failed
to kill target cells pulsed with the peptides that have a mutation from Lys to Arg or Gln at amino acid 585 which
is present in some prototype human immunodeficiency virus type 1 strains, e.g., ADA, JFL, SC, ALA1, BAL1,
SF2, VRF, SF33, and WMJ2. This finding that a mutation at amino acid 585 on gp4l results in nonrecognition
by human leukocyte antigen A24-restricted CD8+ cytotoxic T lymphocytes suggests that antigenic variation at
T-cell epitopes contributes to the failure of immune control of human immunodeficiency virus type 1 infections.
There is a failure of the immune system to eliminate
human immunodeficiency type 1 (HIV-1)-infected cells. It is
assumed that the HIV-1-specific cytotoxic T-lymphocyte
(CTL) responses help to limit virus replication by destroying
virus-infected cells in vivo but eventually the infection
progresses and immunodeficiency is complicated by numer-
ous infections with opportunistic agents. There have been
several reports concerning HIV-1-specific CTL which have
been detected directly by using peripheral blood mononu-
clear cells (PBMC) of HIV-1-infected individuals (5, 9, 11,
12, 15, 16); therefore, there is evidence of ongoing antigenic
stimulation by HIV-1-infected cells during HIV-1 infection.
To learn more precisely about human T-cell responses to
HIV-infected cells, we and others have attempted to clone
HIV-1-specific T cells (3, 6, 13, 16). The amount of available
information which defines virus-specific T-cell epitopes at
the clonal level is limited. For example, only two epitopes
restricted by different major histocompatibility complex
class II-restricting elements have been defined on HIV-1
gpl6O (3, 13). Recently, our laboratory defined in detail the
first CD8+ CTL epitope on gp4l, amino acids (aa) 768 to 778,
which was restricted by human leukocyte antigen (HLA)
A3.1 (14a). In addition, we demonstrated that a CD8+ T-cell
clone specific for this epitope on gp4l recognized and lysed
target cells infected with an HIV-1 strain which shared this
sequence, similar to lysis observed by using vaccinia virus/
gpl60 hybrid virus-infected cells or target cells pulsed with
synthetic peptides matching the sequence. Plata et al. used
peptide-coated target cells and bronchoalveolar lavage effec-
tor cells to demonstrate an HLA A2-restricted epitope at aa
381 to 392 on gpl2O (11). Recently, Clerici et al. reported that
CD8+ CTL of some HIV-1-infected individuals recognized
four synthetic peptides based on the HIV-1 IIIB sequence.
These experiments were done in bulk culture, and HLA A2
was identified as a restricting element for all four peptides,
and Al or B8 may also have presented some peptides (1).
* Corresponding author.
In this report, we describe a second CD8+ CTL epitope on
gp41 which was localized to aa 584 to 591 of gp4l by using
the PBMC of another HIV-1-infected donor. The clone
recognized target cells expressing gp4l of the HIV-1 IIIB
and MN prototype strains and also killed target cells pulsed
with a synthetic peptide reflecting the sequence of the HIV-1
JRCSF strain. This clone failed to recognize target cells
pulsed with peptides with a mutation from K to R or Q at aa
585 and thus failed to kill target cells expressing sequences of
some prototype HIV-1 strains which have been sequenced,
for example, ADA, JFL, SC, ALA1, BAL1, SF2, VRF,
SF33, and WMJ2. Therefore, a mutation at aa 585 on gp41
results in nonrecognition by HLA A24-restricted CD8+
CTL.
MATERIALS AND METHODS
Recombinant vaccinia viruses. Recombinant vaccinia vi-
ruses that express four different N-terminal overlapping Env
proteins of 502, 635, 747, and 851 aa of the BH8 isolate were
constructed as previously described (2). HeLa cells infected
with these viruses were trypsinized, sonicated, and stored at
-80°C before use.
Synthesis of peptides. Synthetic peptides of HIV-1 gpl60
(NL43 strain) were constructed as previously described
(14a). Some peptides were synthesized by the RaMPS sys-
tem (Du Pont, Boston, Mass.). The amino acid composition
of each peptide was analyzed by using the Waters PICO
TAG Amino Acid Analysis System. Envelope protein se-
quences and numbering of residues are based on the report
of Myers et al. (8).
Establishment of an HIV-1 env-specific CTL clone. CTL
clones were generated as previously described (6). In brief,
PBMC of an asymptomatic HIV-1-seropositive subject were
seeded at 50 per well in 96-well plates and cultured with
CD3-specific monoclonal antibody 12F6 and irradiated allo-
geneic PBMC from a normal healthy adult as feeder cells in
RPMI 1640 medium containing 10% fetal calf serum, antibi-
otics, and recombinant human interleukin-2 (Cellular Prod-
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ucts, Buffalo, N.Y.). Plates were fed once a week with fresh
medium, and 2 weeks later the cells were restimulated with
12F6 and allogeneic feeders. After 4 weeks, the cells were
screened for lytic activity on autologous B-lymphoblastoid
cell lines (B-LCL) infected with vPE16, which expresses
HIV-1 gpl60 or the NYCBH strain of vaccinia virus (nega-
tive control). T-cell lines demonstrating specific lysis of
targets infected with vPE16 were cloned at limiting dilution
in the presence of 12F6, recombinant human interleukin-2,
and feeder cells.
CTL assay. CTL activity was measured in a standard Cr
release assay as previously described (6). In brief, Epstein-
Barr virus-transformed B-LCL were infected at 20 PFU per
cell with recombinant vaccinia virus containing the entire
gene for HIV-1 gpl60 or truncated segments of the gene or
with vaccinia virus as a negative control for 14 to 15 h. The
cells were labeled with Na-chromate and used as target cells.
In experiments with peptide-pulsed target cells, the cells
were labeled with Na-chromate before pulsing with synthetic
peptides for 1 h. Effector cells were added to target cells in
triplicate and incubated for 4 h at 37°C. Percent specific lysis
was calculated by the formula 100 x [(mean test counts per
minute - mean spontaneous counts per minute)/(mean max-
imal counts per minute - mean spontaneous counts per
minute)]. Spontaneous release of target cells was always less
than 30%.
Phenotypic analysis of cells. Cells were incubated with a
fluorescein isothiocyanate-labeled monoclonal antibody spe-
cific for CD3, CD4, CD8, and CD16; washed; and analyzed
by fluorescence-activated cell sorter (Beckton Dickinson,
San Jose, Calif.).
Nucleotide sequence accession number. The GenBank ac-
cession number of HIV NL43, to which we referred for
synthesis of the peptides used here, is M19921.
RESULTS
We used methods previously reported by Walker et al. and
ourselves (6, 16) to establish long-term T-cell lines directly
from the PBMC of an HIV-1-infected donor. Wells were
seeded with 50 PBMC per well and supported by irradiated
allogeneic feeder cells. Well 137 lysed an autologous B-cell
line infected with vaccinia virus/gpl60 (IIIB) but did not lyse
control target cells infected with vaccinia virus or with
vaccinia virus expressing HIV gag or pol (data not shown).
To localize the region of gpl60 that was recognized by this
CTL line, target cells were infected with vaccinia virus
expressing truncated regions of envelope gpl60. The results
in Table 1 show that the epitope lies between aa 502 and 635
on gpl60. In the same experiment, monoclonal antibodies to
cross-reactive framework determinants on HLA class I
(W6/32) or II (DP, DQ, and DR) were added to the assay.
Significant reduction of cytotoxicity was observed only
when the monoclonal antibody to HLA class I was used.
T-cell line 137 was tested on target cells pulsed with
synthetic peptides based on the sequence of gp4l of HIV-1
IIIB, because line 137 killed target cells infected with vac-
cinia virus expressing gpl60 but not gpl20 (Table 1). The
results shown in Table 2 indicate that the CTL line recog-
nized target cells that were pulsed with peptide containing aa
564 to 591, but target cells pulsed with peptides representing
aa 550 to 574 or 587 to 604 were not recognized.
Parental T-cell line 137 was subcloned at 0.3 and 3.0 cells
per well. A number of wells showed growth, and the cells in
most wells showed specific killing of autologous B cells
infected with vaccinia virus/gpl60 or after pulsing with
TABLE 1. Localization of epitope gpl60 with recombinant
vaccinia viruses containing truncated HIV-1 env genes
Truncated Env % Specific
Virus protein (amino acid % Scif
residuesa) or MAbb 1y5i
Recombinant vaccinia viruses
vPE16 1-851 94.8
vPE17 1-747 91.8
vPE18 1-635 82.8
vPE8 1-502 0.0
Vaccinia virus 0.6
Recombinant vaccinia virus
vPE16 Anti-class I 56.4
Anti-DP 87.5
Anti-DQ 78.5
Anti-DR 87.6
None 94.8
a Numbering of amino acid residues is based on the HIV-1 IIIB strain.b MAb, monoclonal antibody.
CTL activity was determined at an effector-target cell ratio of 4.
peptide 84. Subclone 137.6 provided a high level of killing of
both of these target cells, so it was used for characterization.
Clone 137.6 was analyzed by fluorescence-activated cell
sorter with monoclonal antibodies to CD3, CD4, and CD8,
which revealed it to be a CD8+ clone, since all of the cells
present were CD3+, CD8+, and CD4- (data not shown).
To define the epitope recognized by clone 137.6 in detail,
a series of synthetic peptides representing segments con-
tained within aa 564 to 591 were prepared. The results shown
in Table 3 indicate that the epitope recognized by 137.6 and
another subclone, 137.19, is contained in aa 580 and 591.
We then prepared a series of synthetic peptides with
N-terminal truncations from aa 580 to 591. In addition, we
synthesized peptides for the region from 580 to 591 to
represent mutant virus strains at sites in this region on the
basis of published sequence data on HIV-1 strains (8). The
results shown in Table 4 indicate that aa 584 to 591 contained
the epitope recognized by the CD8+ clone. Lysis of target
cells pulsed with peptides representing mutations in the
sequences of other prototype strains indicated that a change
from K to R or Q at aa 585 resulted in nonrecognition by the
clone. A peptide based on the sequence of JRCSF, which
has a mutation at 590 from L to M, was recognized.
Therefore, certain strains, such as IIIB, MN, and JRCSF,
were recognized by this CD8+ CTL clone but a mutation at
TABLE 2. Mapping of the epitope using synthetic
envelope peptides
Envelope Amino acid % Specific
peptide residues lysisa
80 510-530 -0.6
81 522-546 0.0
82 534-554 -2.7
83 550-573 1.9
84 564-591 33.9
85 587-607 2.5
86 599-625 -0.4
87 616-642 0.3
a Autologous B-LCL were pulsed with each peptide at a concentration of 50
,ug/ml for 1 h and used for CTL assay at an effector-target cell ratio of 4.
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TABLE 3. Epitope mapping using overlapping synthetic peptides
% Specific lysisa
Envelope Amino acid by clone:
peptide residues
137.6 137.19
84 564-591 42.3 60.7
84A 555-570 -4.7 -2.7
84B 560-575 -2.5 -1.8
84C 565-580 -1.4 2.4
84D 570-585 0.7 2.2
84E 575-590 -4.2 -3.4
84F 580-595 54.3 43.0
84G 585-600 2.1 -1.1
a Autologous B-LCL were pulsed with each peptide (50 pg/ml) and tested
for CTL assay at an effector-target cell ratio of 5.
site 585 from K to R or Q resulted in nonrecognition of a
number of other prototype strains, for example, ADA, JFL,
SC, ALA1, BALl, SF2, VFR, SF33, and WMJ2.
Experiments were performed to define the HLA-restrict-
ing element used by this CD8+ CTL clone. The results
shown in Table 5 indicate that allogeneic target cells which
share A24 as the common HLA antigen were recognized and
lysed by clone 137.6 when they expressed this epitope.
Allogeneic target cells which shared another HLA antigen,
A1, B8, or B39, were not lysed.
DISCUSSION
Several reports have defined HIV-1-specific T-cell
epitopes on gag and pol, but there is a relative scarcity of
reports of CD8+ CTL epitopes on envelope gpl6O. Earlier,
Plata et al. (11) noted that killing of peptide-pulsed target
cells by bronchoalveolar effector cells was A2 restricted and
localized to the region from aa 381 to 392 on gpl20. Re-
cently, we defined an epitope on gp4l localized between 768
and 778 (14a). Clerici et al. (1) recently reported that
synthetic peptides representing four sites on gp160 of the
IIIB strain were recognized by CD8+ T cells of some
HIV-1-seropositive donors. The epitopes were not defined in
detail. HLA A2 restriction was reported with the four
peptides, but Al or B8 may also have presented some
peptides. Thus, only a few human CD8+ CTL epitopes have
been defined on the HIV-1 envelope glycoprotein. The
reasons for this discrepancy between the reported numbers
of epitopes on HIV-1 env and epitopes on gag and pol are
TABLE 4. Fine epitope mapping using truncated
synthetic peptides
Envelope Amino acid Amino acid % Specific lysisa
peptide sequence residues by clone 137.6
84F AVERYLKDQQLL 580-591 42.2
84F1 VERYLKDQQLL 581-591 54.3
84F2 ERYLKDQQLL 582-591 43.3
84F3 RYLKDQQLL 583-591 59.9
84F4 YLKDQQLL 584-591 48.6
84F5 LKDQQLL 585-591 -8.8
8F46 YLKDQQL 584-590 2.2
ib YLRDQQLL 584-591 -5.8
II" YLQDQQLL 584-591 -3.7
iiib YLKDQQLM 584-591 37.7
a Autologous B-LCL were pulsed with each peptide (50 jig/ml) and tested
for CTL assay at an effector-target cell ratio of 5.b Sequence data are from the compilation of Myers et al. (8).
TABLE 5. HLA restriction of clone 137.6
Target HLA antigens with the following phenotype: %
B-LCL SpecificClass I Class II lysisa
11 Al, A24, B8, B39, DR3, DR6, DQwl, 59.8
Cw- DQw2
CG A1, A2, B8, B17, NTb -2.7
Cw6, Cw7
MTT A2, A24, B49, NT 25.2
BwS5, Cw3
MHN A24, A30, B13, NT 54.0
BwS5, Cw4, Cw6
15 A2, A24, B35, B49, DR2, DR5, DQwl, 55.7
Cw4, Cw8 DQw3
JC A3, A24, B35, Cw4 DR2, DR4, DQw1, 35.3
DQw3
BI A26, A29, B35, DR5, DQw1, 6.1
B39, Cw4 DQw3
a Autologous and allogeneic B-LCL which share an HLA antigen(s) with
the donor were infected with vPE18 recombinant vaccinia virus and used for
CTL assay at an effector-target cell ratio of 5.
b NT, not tested.
not known; however, it may be due in part to the methods
used to identify HIV-specific CTL clones. We and other
investigators screen candidate human T-cell clones for
HIV-1 specificity by the ability to lyse autologous B cells
infected with vaccinia virus expressing genes for the proto-
type IIIB virus (6, 16). Thus, the only T-cell lines which are
positive in screening cytotoxicity assays are those which
specifically lyse vaccinia virus expressing HIV-1 IIIB genes.
Since the degree of variation of the envelope glycoprotein
exceeds that of the Gag, Pol, or other internal proteins (8), it
might be expected that multiple mutations in gpl60 between
(i) the strain(s) of the virus infecting the individual and
inducing the CD8+ CTL responses and (ii) the sequence in
the region of the IIIB epitope of gpl60 are different. It is
likely that CD8+ CTL clones that recognize autologous
virus-infected cells but not vaccinia virus/gpl60 IIIB-in-
fected cells are not detected.
Two reports have described CD4+ CTL epitopes on the
envelope glycoprotein, and both reports have involved the
use of recombinant baculovirus-expressed gpl60, either as
an in vitro stimulus of uninfected donor PBMC (13) or after
immunization of an HIV-1-seronegative individual with ex-
perimental recombinant baculovirus-expressed gpl60 vac-
cine (10). Following administration of the experimental
vaccine, a CD4+ HLA DPw4-restricted T-cell clone was
derived and mapped to a region which overlaps the epitope
on gp4l detected with a CD8+ CTL clone from an infected
donor described in this report (3). There have been several
reports in murine T-cell systems of specific T-cell determi-
nants on proteins which overlap epitopes that can be pre-
sented to CD4 and CD8 T cells (14). We have defined a
highly conserved HLA Cw3-restricted CD8+ CTL epitope
on HIV-1 p24 aa 140 to 148 (6) and recently reported an HLA
DQ-restricted CD4+ CTL epitope to p24 aa 145 to 150 which
partly overlaps the CD8+ CTL epitope (6a). In these cases,
partial overlap of epitopes was observed but fine epitope
mapping indicated differential recognition of sequences by
CD4+ and CD8+ T cells. These observations indicate that
certain regions of viral proteins, and other antigens, contain
overlapping regions of peptides that are immunogenic for
both CD4 and CD8+ T-cell responses. This has practical
potential, since the ability to interact with both class I and
VOL. 66, 1992
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class II major histocompatibility complex antigens suggests
that T cells of a larger number of individuals would recognize
such epitopes on virus-infected cells or after immunization
with a vaccine which contains these peptide regions.
The importance of CD8+ CTL responses in HIV-1 infec-
tions remains to be determined. In the absence of an
appropriate animal model, it has not been possible to test
directly the effect of adoptive transfer of CTL clones specific
for HIV-1. Studies with the Hu/SCID mouse model which
should be of interest are being attempted. One of the major
questions concerning the biology of HIV-1-specific CTL
responses is their failure to eliminate HIV-1-infected cells
and resolve HIV-1 infections despite evidence that virus-
specific CD8+ CTL can cure T-cell-deficient mice with other
virus infections (7), including persistent established lympho-
cytic choriomeningitis virus infection in nude mice (4). The
ability of HIV-1 and other lentiviruses to insert provirus into
host cell DNA (17), antigenic variation at T-cell epitopes
such as those described in this report, and the impact of
HIV-1 infections and immune responses to HIV-1-infected
immunocompetent cells may contribute to the failure of
human immune systems to resolve HIV-1 infections.
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